What Catalysts Are Driving the Changing Narrative for Regeneron?

Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on ...

Market Starting To Embrace The 'New' Regeneron

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Ophthalmology Times

Regeneron receives another CRL for its Eyelea 8 mg

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

Regeneron Pharmaceuticals, Inc. (REGN) Stock forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Ophthalmology Times

Anti-VEGF innovations in retinal disease: From molecules to medicine

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...
Zacks Investment Research on MSN

Amgen's Q3 Earnings in the Cards: Here's What to Expect

Amgen AMGN will report third-quarter 2025 results on Nov. 4, before market open. In the last reported quarter, the company's ...

Adhoc: Sandoz Group AG: Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded

Sales Result/9 Month figures Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded 30-Oct-2025 / 07:00 CET/CEST Release ...

FDA to Speed Biosimilar Approvals in Push to Cut Drug Costs (1)

The FDA is planning to speed approvals of highly similar copies of expensive biologic drugs, the latest effort in President ...